Physician profile
Robert J Schoderbek, JR.
NPI 1043425499
$8,196.76
in general payments reported to CMS, 2019-2025
13 companies · $474 in 2025
The $474 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,611 · 2020: $1,233 · 2021: $206 · 2022: $1,301 · 2023: $195 · 2024: $176 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $845.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Peerless Surgical INC. | $3,387.12 | 2019-2025 | |
| Smith+Nephew, INC. | $1,986.01 | 2019-2025 | Clancy, Ultrabutton |
| Exactech, INC. | $1,116.72 | 2019-2023 | |
| Arthrex, INC. | $925.34 | 2019-2021 | |
| Karl Storz Endoscopy-America | $161.94 | 2019 | |
| Miach Orthopaedics, INC. | $141.95 | 2025 | |
| Zimmer Biomet Holdings, INC. | $131.75 | 2025 | Juggerknotless Soft Anchor |
| Si-Bone, INC. | $82.54 | 2022-2023 | |
| Vericel Corporation | $77.06 | 2019-2025 | Maci |
| Boston Scientific Corporation | $64.10 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Bioventus LLC | $55.83 | 2025 | Xcell, Durolane |
| Depuy Synthes Sales INC. | $37.42 | 2021 | |
| Davol INC. | $28.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schoderbek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.